替莫唑胺化疗方案联合全脑放疗治疗非免疫功能缺陷PCNSL的临床观察  

Clinical Study of Temozolomide Combined with Whole Brain Radiotherapy in the Treatment of PCNSL Patients with Non-immune Deficiency

作　　者：李鸿波[1] LI Hongbo.(Second People＇s Hospital of Jiaozuo,Jiaozuo ,45400)

机构地区：[1]河南省焦作市第二人民医院,454000

出　　处：《实用癌症杂志》2018年第4期661-663,共3页The Practical Journal of Cancer

摘　　要：目的研究替莫唑胺化疗方案联合全脑放疗治疗非免疫功能缺陷PCNSL的临床效果。方法回顾性分析应用替莫唑胺化疗方案联合全脑放疗治疗的168例非免疫功能缺陷PCNSL患者的基本资料、临床表现、化疗周期、化疗疗效、不良反应、生存分析、随访时间等数据信息,研究了替莫唑胺化疗方案联合全脑放疗治疗非免疫功能缺陷PCNSL患者的临床疗效。结果 168例患者治疗后随访时间为0~24个月;平均生存期为(11.8±2.3)个月。CR 51例(30.35%)、PR 63例(37.50%)、SD 23例(13.69%)、PD 31例(18.45%)、有效率67.86%以及临床控制率81.55%。不良反应主要有:贫血、骨髓抑制、疲劳、恶心呕吐等。结论替莫唑胺化疗方案联合全脑放疗治疗能够比较有效地提高患者生存率,值得临床推广应用。Objective To observe the clinical efficacy of temozolomide chemotherapy combined with whole brain radio- therapy in the treatment of non-immune dysfunction PCNSL. Methods Retrospective analysis of temozolomide chemotherapy combined with whole brain radiotherapy in the treatment of 168 cases of non-immune dysfunction in patients with PCNSL basic in- formation, clinical manifestations, cycles of chemotherapy, chemotherapy, adverse reaction and survival analysis, follow-up data, study the clinical curative effect of the treatment of patients with non-immune defect PCNSL temozolomide chemotherapy combined with whole brain radiotherapy. Results 168 patients were followed up for 0 to 24 months after treatment;the average survival time was （11. 8 ±2. 3） months. CR51 cases（30. 35%）,PR63 cases（37. 50%）,SD23 cases（13. 69%）,PD31 cases （ 18.45 % ） , and effective rate 67.86% and clinical control rate 81.55 %. Adverse reactions are ： anemia, bone marrow suppres- sion, fatigue, nausea and vomiting. Conclusion Temozolomide chemotherapy combined with whole brain radiotherapy can effec- tively improve the survival rate of patients, and is worthy of clinical application.

关 键 词：替莫唑胺 全脑放疗 非免疫功能缺陷 原发中枢神经系统淋巴瘤 

分 类 号：R730.5[医药卫生—肿瘤]